Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-17

Thanks mate, always love proactive investors on here reaching out to management.

Imo, this hasn't been announced intentionally to supress the share price. Why else would management not keep share holders in the know about 2 further distribution agreements, irrespectice of the size of the distributor. Yet conveniently and briefly mention it following the placement. Again, the movement has been questionable in the sense that its been strategically reduced for an entry price for these sophs with the placement and director to buy in, in addition to constantly being capped before at ~11c, and now also whenever some buying interest appears, ridiculous walls appear also.

However, I think the market is waking up and sensing the value here so some nice line wipes have been happening, including a few by myself in the low 7s last few days.

With regards to orders, I'd love to see the quantity as some holders have mentioned FebriDX will be in packets of 10, so roughly $200 per packet, and 50% profit if I'm not mistaken. Furthermore, I look forward to the uptake because if hospitals or clinics are going thru a packet or packets in a day, then the ongoing profit will be substantial, and that's just for Febridx at this stage. Exciting times ahead for Lumos.

As always, dyor as this is not financial advice.

GLTAH